Why Hims & Hers Stock Popped Tuesday, but Eli Lilly and Novo Nordisk Dropped
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2025
0mins
Source: NASDAQ.COM
Hims & Hers Health Performance: Hims & Hers stock surged 11.2% after reporting a sales beat with a 111% year-over-year increase, despite an earnings miss of $0.20 per share compared to the expected $0.23. The company forecasts continued growth, projecting sales between $2.3 billion and $2.4 billion for the year.
Impact on Competitors: The positive outlook for Hims & Hers is seen as a competitive threat to larger drugmakers like Eli Lilly and Novo Nordisk, whose stocks fell by 3.2% following the news, indicating concerns about sharing future profits in the GLP-1 market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 27.760
Low
16.50
Averages
32.95
High
60.00
Current: 27.760
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Acquires Eucalyptus to Expand Canadian Market Reach
- Acquisition Completed: Hims & Hers has finalized its acquisition of Eucalyptus, marking a significant investment in the Canadian market that is expected to enhance its competitive edge in personalized health management.
- Market Pioneer: Since its launch in 2025, Hims & Hers has become the first platform to offer generic semaglutide to eligible Canadians, addressing the growing demand for personalized weight management solutions.
- Service Expansion: By integrating Juniper's platform, Hims & Hers will be able to provide a broader range of health services, including sexual health and hair loss treatments, filling critical service gaps in Canada.
- Localized Operations: Hims & Hers emphasizes collaboration with local healthcare providers to ensure patients receive care backed by local expertise and support, thereby enhancing patient trust and satisfaction.
See More
Hims & Hers Completes Acquisition of Eucalyptus for $240M
- Acquisition Completed: Hims & Hers Health has finalized its acquisition of Eucalyptus, paying approximately $240 million in cash, thereby gaining access to markets in Australia, Canada, and Japan, significantly expanding its international business footprint.
- Market Expansion: Eucalyptus is the parent company of Juniper, Pilot, Kin, and Software, and this acquisition allows Hims & Hers to leverage Eucalyptus's brands and technology, enhancing its competitive position in the global telehealth market.
- Strategic Implications: By acquiring Eucalyptus, Hims & Hers not only enters new markets but also capitalizes on Eucalyptus's existing customer base and product offerings, driving future revenue growth and increasing market share.
- Investor Confidence: Following the acquisition announcement, Hims & Hers's stock price rose, indicating a positive market reaction to its expansion strategy and further bolstering investor confidence in the company's future prospects.
See More
Analysis of Hims & Hers Stock Volatility
- Market Volatility: Hims & Hers stock exhibited significant volatility during afternoon trading on May 28, 2026, reflecting market uncertainty regarding its future performance, which could impact investor confidence.
- Price Dynamics: As of May 28, 2026, Hims & Hers stock rose by 6.20%, indicating a positive market reaction in the short term, but the long-term trend remains to be seen to assess sustainability.
- Investor Attention: Due to its volatility, Hims & Hers has become a focal point for investors, potentially attracting short-term traders and those with higher risk appetites, thereby affecting its market liquidity.
- Video Release Impact: The video published on May 30, 2026, may further influence market perceptions of Hims & Hers stock, particularly in analyzing its volatility and future potential.
See More
Analysis of Hims & Hers Stock Volatility
- Market Volatility: Hims & Hers (NYSE: HIMS) is identified as one of the most volatile stocks in the market, indicating investor uncertainty regarding its future performance, which could adversely affect its short-term stock price.
- Lack of Investment Recommendations: Despite the attention surrounding Hims & Hers Health, it was not included in the current top 10 stocks recommended by The Motley Fool Stock Advisor, reflecting a cautious market sentiment about its growth potential.
- Historical Return Comparison: Compared to previously recommended stocks like Netflix and Nvidia, which achieved returns of 463,900% and 1,294,401% respectively, Hims & Hers' absence from the recommendation list highlights its relative disadvantage in the eyes of investors.
- Investor Community Engagement: Although Hims & Hers is not recommended, The Motley Fool still holds shares in the company, indicating its significance within the investor community and potentially attracting investors interested in high-risk opportunities.
See More
Hims & Hers Expands Health Services Partnerships
- Partnership Expansion: Hims & Hers has added eight new partners to its Benefits program, broadening its service offerings in fitness, nutrition, and women's health, which enhances its competitive position as a comprehensive healthcare platform.
- International Market Entry: The company launched generic Semaglutide in Canada, marking its first international rollout of a generic GLP-1 product, which is expected to drive international expansion of its weight-loss business and diversify revenue streams.
- AI Healthcare Innovation: Hims introduced Labs AI, providing personalized analysis of lab results and health risks, indicating a strategic move into AI healthcare tools aimed at improving user experience and health management capabilities.
- Investor Sentiment Fluctuation: While former Netflix CFO David Wells' purchase of Hims shares signals confidence, Bank of America has lowered its price target, reflecting market skepticism about the company's growth prospects amid increasing competition in the GLP-1 market.
See More
Hims & Hers Expands Health Benefits Program
- Health Benefits Expansion: Hims & Hers has announced the expansion of its health benefits program to include ten partners, such as MyFitnessPal and HelloFresh, aiming to enhance user overall health experience by integrating top tools across nutrition, fitness, and women's health.
- Personalized Service Enhancement: New partners offer diverse services, including AI coaching from iFIT and strength training from Ladder, helping users create science-backed workout plans tailored to their personal goals, thereby increasing user engagement and satisfaction.
- Subscription Incentives to Attract Users: Hims & Hers is providing various discounts for new services, such as a 15% discount on MyFitnessPal and eleven free meals from HelloFresh, aiming to attract more users through affordable health options and enhance customer loyalty.
- Commitment to Continuous Growth: Hims & Hers plans to continue adding new partners to further enrich its health benefits offerings, reflecting the company's long-term commitment to user health and aiming to enhance market competitiveness by providing comprehensive health management tools.
See More
Hims & Hers Acquires Eucalyptus to Expand Canadian Market Reach
- Acquisition Completed: Hims & Hers has finalized its acquisition of Eucalyptus, marking a significant investment in the Canadian market that is expected to enhance its competitive edge in personalized health management.
- Market Pioneer: Since its launch in 2025, Hims & Hers has become the first platform to offer generic semaglutide to eligible Canadians, addressing the growing demand for personalized weight management solutions.
- Service Expansion: By integrating Juniper's platform, Hims & Hers will be able to provide a broader range of health services, including sexual health and hair loss treatments, filling critical service gaps in Canada.
- Localized Operations: Hims & Hers emphasizes collaboration with local healthcare providers to ensure patients receive care backed by local expertise and support, thereby enhancing patient trust and satisfaction.
See More
Hims & Hers Completes Acquisition of Eucalyptus for $240M
- Acquisition Completed: Hims & Hers Health has finalized its acquisition of Eucalyptus, paying approximately $240 million in cash, thereby gaining access to markets in Australia, Canada, and Japan, significantly expanding its international business footprint.
- Market Expansion: Eucalyptus is the parent company of Juniper, Pilot, Kin, and Software, and this acquisition allows Hims & Hers to leverage Eucalyptus's brands and technology, enhancing its competitive position in the global telehealth market.
- Strategic Implications: By acquiring Eucalyptus, Hims & Hers not only enters new markets but also capitalizes on Eucalyptus's existing customer base and product offerings, driving future revenue growth and increasing market share.
- Investor Confidence: Following the acquisition announcement, Hims & Hers's stock price rose, indicating a positive market reaction to its expansion strategy and further bolstering investor confidence in the company's future prospects.
See More
Analysis of Hims & Hers Stock Volatility
- Market Volatility: Hims & Hers stock exhibited significant volatility during afternoon trading on May 28, 2026, reflecting market uncertainty regarding its future performance, which could impact investor confidence.
- Price Dynamics: As of May 28, 2026, Hims & Hers stock rose by 6.20%, indicating a positive market reaction in the short term, but the long-term trend remains to be seen to assess sustainability.
- Investor Attention: Due to its volatility, Hims & Hers has become a focal point for investors, potentially attracting short-term traders and those with higher risk appetites, thereby affecting its market liquidity.
- Video Release Impact: The video published on May 30, 2026, may further influence market perceptions of Hims & Hers stock, particularly in analyzing its volatility and future potential.
See More
Analysis of Hims & Hers Stock Volatility
- Market Volatility: Hims & Hers (NYSE: HIMS) is identified as one of the most volatile stocks in the market, indicating investor uncertainty regarding its future performance, which could adversely affect its short-term stock price.
- Lack of Investment Recommendations: Despite the attention surrounding Hims & Hers Health, it was not included in the current top 10 stocks recommended by The Motley Fool Stock Advisor, reflecting a cautious market sentiment about its growth potential.
- Historical Return Comparison: Compared to previously recommended stocks like Netflix and Nvidia, which achieved returns of 463,900% and 1,294,401% respectively, Hims & Hers' absence from the recommendation list highlights its relative disadvantage in the eyes of investors.
- Investor Community Engagement: Although Hims & Hers is not recommended, The Motley Fool still holds shares in the company, indicating its significance within the investor community and potentially attracting investors interested in high-risk opportunities.
See More
Hims & Hers Expands Health Services Partnerships
- Partnership Expansion: Hims & Hers has added eight new partners to its Benefits program, broadening its service offerings in fitness, nutrition, and women's health, which enhances its competitive position as a comprehensive healthcare platform.
- International Market Entry: The company launched generic Semaglutide in Canada, marking its first international rollout of a generic GLP-1 product, which is expected to drive international expansion of its weight-loss business and diversify revenue streams.
- AI Healthcare Innovation: Hims introduced Labs AI, providing personalized analysis of lab results and health risks, indicating a strategic move into AI healthcare tools aimed at improving user experience and health management capabilities.
- Investor Sentiment Fluctuation: While former Netflix CFO David Wells' purchase of Hims shares signals confidence, Bank of America has lowered its price target, reflecting market skepticism about the company's growth prospects amid increasing competition in the GLP-1 market.
See More
Hims & Hers Expands Health Benefits Program
- Health Benefits Expansion: Hims & Hers has announced the expansion of its health benefits program to include ten partners, such as MyFitnessPal and HelloFresh, aiming to enhance user overall health experience by integrating top tools across nutrition, fitness, and women's health.
- Personalized Service Enhancement: New partners offer diverse services, including AI coaching from iFIT and strength training from Ladder, helping users create science-backed workout plans tailored to their personal goals, thereby increasing user engagement and satisfaction.
- Subscription Incentives to Attract Users: Hims & Hers is providing various discounts for new services, such as a 15% discount on MyFitnessPal and eleven free meals from HelloFresh, aiming to attract more users through affordable health options and enhance customer loyalty.
- Commitment to Continuous Growth: Hims & Hers plans to continue adding new partners to further enrich its health benefits offerings, reflecting the company's long-term commitment to user health and aiming to enhance market competitiveness by providing comprehensive health management tools.
See More
